162 related articles for article (PubMed ID: 37798609)
1. The Identification of Gamma-Glutamyl Hydrolase in Uterine Corpus Endometrial Carcinoma: a Predictive Model and Machine Learning.
Zhu C; Du Y; Huai Q; Fang N; Xu W; Yang J; Li X; Zhang Y; Zhang X; Dai H; Li X; Wang H; Dai Y
Reprod Sci; 2024 Feb; 31(2):532-549. PubMed ID: 37798609
[TBL] [Abstract][Full Text] [Related]
2. Elevated Expression of Gamma-Glutamyl Hydrolase Is Associated With Poor Prognosis and Altered Immune Signature in Uterine Corpus Endometrial Carcinoma.
Yu C; Qi H; Zhang Y; Zhao W; Wu G
Front Genet; 2021; 12():764194. PubMed ID: 35082830
[TBL] [Abstract][Full Text] [Related]
3. Construction of N-7 methylguanine-related mRNA prognostic model in uterine corpus endometrial carcinoma based on multi-omics data and immune-related analysis.
Zhao J; Zou J; Jiao W; Lin L; Wang J; Lin Z
Sci Rep; 2022 Nov; 12(1):18813. PubMed ID: 36335189
[TBL] [Abstract][Full Text] [Related]
4.
Zhao Q; Chen G; Yang X; Wang T; Yuan S; Meng Q
Comb Chem High Throughput Screen; 2023; 26(2):330-338. PubMed ID: 35379118
[TBL] [Abstract][Full Text] [Related]
5. Machine learning combined with single-cell analysis reveals predictive capacity and immunotherapy response of T cell exhaustion-associated lncRNAs in uterine corpus endometrial carcinoma.
Jiang F; Tao Z; Zhang Y; Xie X; Bao Y; Hu Y; Ding J; Wu C
Cell Signal; 2024 May; 117():111077. PubMed ID: 38311301
[TBL] [Abstract][Full Text] [Related]
6. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
Wang Z; Xing L; Huang Y; Han P
Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
[TBL] [Abstract][Full Text] [Related]
7. A 7-lncRNA signature predict prognosis of Uterine corpus endometrial carcinoma.
Ouyang D; Li R; Li Y; Zhu X
J Cell Biochem; 2019 Oct; 120(10):18465-18477. PubMed ID: 31168849
[TBL] [Abstract][Full Text] [Related]
8. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
[TBL] [Abstract][Full Text] [Related]
9. Prognostic signature construction and immunotherapy response analysis for Uterine Corpus Endometrial Carcinoma based on cuproptosis-related lncRNAs.
Zhang X; Ye Z; Xiao G; He T
Comput Biol Med; 2023 Jun; 159():106905. PubMed ID: 37060773
[TBL] [Abstract][Full Text] [Related]
10. Identification of an eight-m6A RNA methylation regulator prognostic signature of uterine corpus endometrial carcinoma based on bioinformatics analysis.
Miao C; Fang X; Chen Y; Zhao Y; Guo Q
Medicine (Baltimore); 2021 Dec; 100(49):e27689. PubMed ID: 34889221
[TBL] [Abstract][Full Text] [Related]
11. Identifying immune subtypes of uterine corpus endometrial carcinoma and a four-paired-lncRNA signature with immune-related lncRNAs.
Li N; Yu K; Lin Z; Zeng D
Exp Biol Med (Maywood); 2022 Feb; 247(3):221-236. PubMed ID: 34704492
[TBL] [Abstract][Full Text] [Related]
12. RNA modification regulator DDC in endometrial cancer affects the tumor microenvironment and patient prognosis.
Zhao H; Shi C; Zhao G; Liu J; Wang X; Liang J; Li F
Sci Rep; 2023 Oct; 13(1):18057. PubMed ID: 37872211
[TBL] [Abstract][Full Text] [Related]
13. High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.
Shubbar E; Helou K; Kovács A; Nemes S; Hajizadeh S; Enerbäck C; Einbeigi Z
BMC Cancer; 2013 Feb; 13():47. PubMed ID: 23374458
[TBL] [Abstract][Full Text] [Related]
14. m
Fang F; Wang P; Huang H; Ye M; Liu X; Li Q
BMC Cancer; 2022 Dec; 22(1):1364. PubMed ID: 36581816
[TBL] [Abstract][Full Text] [Related]
15. Ferroptosis-Related lncRNA for the Establishment of Novel Prognostic Signature and Therapeutic Response Prediction to Endometrial Carcinoma.
Zhou XY; Dai HY; Zhang H; Zhu JL; Hu H
Biomed Res Int; 2022; 2022():2056913. PubMed ID: 35937391
[TBL] [Abstract][Full Text] [Related]
16. Identification of an Immune-Related LncRNA Prognostic Signature in Uterine Corpus Endometrial Carcinoma Patients.
Sun XX; Wen HQ; Zhan BX; Yang P
Clin Lab; 2021 Nov; 67(11):. PubMed ID: 34758230
[TBL] [Abstract][Full Text] [Related]
17. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
Chen Y
Front Genet; 2022; 13():912037. PubMed ID: 35937995
[No Abstract] [Full Text] [Related]
18. Integrated bioinformatics analysis and experimental validation reveals fatty acid metabolism-related prognostic signature and immune responses for uterine corpus endometrial carcinoma.
Guo C; He Y; Chen L; Li Y; Wang Y; Bao Y; Zeng N; Jiang F; Zhou H; Zhang L
Front Oncol; 2022; 12():1030246. PubMed ID: 36439473
[TBL] [Abstract][Full Text] [Related]
19. MCM10: An effective treatment target and a prognostic biomarker in patients with uterine corpus endometrial carcinoma.
Chen J; Wu S; Wang J; Han C; Zhao L; He K; Jia Y; Cui M
J Cell Mol Med; 2023 Jun; 27(12):1708-1724. PubMed ID: 37246638
[TBL] [Abstract][Full Text] [Related]
20. Glycosyltransferase-related prognostic and diagnostic biomarkers of uterine corpus endometrial carcinoma.
Wu J; Zhou X; Ren J; Zhang Z; Ju H; Diao X; Jiang S; Zhang J
Comput Biol Med; 2023 Sep; 163():107164. PubMed ID: 37329616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]